CSF ascites is a very rare complication of ventriculoperitoneal (VP) shunt procedure. No definite explanation has been offered for the inability of the peritoneum to absorb the CSF. Two children who underwent VP shunting for hydrocephalus, presented with ascites 3 (1/2) years and 4 months respectively, after the shunt was placed. The treatment of choice is conversion of the VP shunt to a ventriculoatrial shunt.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ascites production and prognosis after ventriculoperitoneal shunt for diffuse midline gliomas in children: A case series.
Medicine (Baltimore)
October 2024
Department of Clinical Laboratory, Guangdong Sanjiu Brain Hospital, Guangzhou, China.
Rationale: DMG is a highly invasive and lethal type of brain tumor. As these tumors progress, they often compromise the CSF circulation, leading to hydrocephalus. Ventriculoperitoneal shunt (VPS) is commonly employed to manage hydrocephalus; however, the complication of VPS-induced ascites, particularly in the presence of tumor cells, is a significant concern that merits attention.
View Article and Find Full Text PDFIntrapleural Migration of Ventriculoperitoneal Shunt due to Negative Intrathoracic Pressure.
Asian J Neurosurg
September 2024
Department of Neurosurgery, Kasturba Medical College and Hospital, Udupi, Karnataka, India.
Article Synopsis
- VP shunts are commonly used to treat infants with aqueductal stenosis, but shunt migration can occur, including rare cases of migration into the thoracic cavity due to negative pressure.* -
- A one-year-old infant with symptoms of raised intracranial pressure underwent emergency VP shunt placement, which initially went well but later resulted in acute breathing issues due to the shunt migrating into the pleural space.* -
- Imaging showed that the shunt likely tunneled improperly during the first surgery, leading to its eventual migration over three months, necessitating an emergency revision to address the issue.*
Gut Microbiota and Cytokine Profile in Cirrhosis.
J Clin Transl Hepatol
August 2024
Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow, Russia.
Article Synopsis
- * Specific cytokines such as IL-1b, IL-6, and TNF-a were associated with both higher levels of harmful gut bacteria and the severity of cirrhosis symptoms like ascites, suggesting a connection between gut health and liver disease progression.
- * The results indicate that certain gut bacteria populations correlate directly with inflammatory cytokine levels, pointing to a potential link between gut dysbiosis and systemic inflammation in cirrhosis patients.
G-CSF induces neutrophil extracellular traps formation and promotes ovarian cancer peritoneal dissemination.
J Leukoc Biol
November 2024
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Epithelial ovarian cancer is characterized by aggressive peritoneal dissemination. Neutrophils are mobilized to peritoneal cavity in some patients with ovarian cancer dissemination; however, its pathological significance remains unknown. This study aimed to investigate the role of neutrophil extracellular traps (NETs) in ovarian cancer dissemination.
View Article and Find Full Text PDFPhase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study).
Technol Cancer Res Treat
July 2024
Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
The prognosis of malignant tumors with peritoneal metastases and cancerous ascites has generally been poor, with limited treatment options. The PRaG regimen, which comprised of hypofractionated radiotherapy, programmed cell death-1 (PD-1) inhibitor, and granulocyte-macrophage colony-stimulating factor (GM-CSF), showed a survival advantage in patients with advanced solid tumors who failed at least the first line of standard systemic treatment. Intraperitoneal infusion of PD-1 inhibitors may be a novel therapeutic strategy for managing malignant ascites.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!